contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


arctic-bioscience-as-arctic-bioscience-board-approval-of-share-capital-increase-related-to-conversion-of-debt

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on bioactive marine raw materials. The company is developing HRO350, a novel drug candidate for the treatment of patients with mild to moderate psoriasis. Dietary supplements are sold globally as both bulk ingredients and finished products under the ROMEGA brand, to both companies and private customers.

Arctic Bioscience

Reference is made to the stock exchange release published by Arctic Bioscience 30th January 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic...

<div class="abstract">Reference is made to the stock exchange release published by Arctic Bioscience 30th January 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic Bioscience.</div>On 3rd February 2025, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company's General Meeting on 26th April 2024, resolved to increase the share capital from NOK 2&nbsp;536&nbsp;955,20 to NOK 2&nbsp;581&nbsp;598,00 by issuance of 446&nbsp;428 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 2,24 per share, including a share premium of NOK 2,14 per share. Further, the Board resolved to increase the share capital from NOK 2&nbsp;581&nbsp;598,00 to NOK 2&nbsp;668&nbsp;934,00 by issuance of 873&nbsp;360 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 2,29 per share, including a share premium of NOK 2,19 per share. The total amount allocated as share premium is NOK 2&nbsp;868&nbsp;014,32. The total subscription amount is NOK 2&nbsp;999&nbsp;993,12. Following the registration of this share capital increase in the Norwegian Register of Business Enterprises, the Company's share capital will be NOK 2&nbsp;668 934 divided into 26&nbsp;689 340 shares, each having a nominal value of NOK 0,10. Minutes from Board Meeting and statement regarding capital increase are attached hereto.This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act. <div></div>

Arctic Bioscience AS: Arctic Bioscience - Board approval of share capital increase related to conversion of debt